The company has recently embarked in the field of cell and cancer therapy and has several on-going collaborations with global research and development institutions. A collaboration agreement was signed with Sirtex Australia to develop and market the use of a patented SIR-Spheres system for the treatment of liver cancer.

An agreement has been signed with the Institute of Cellular Technology to commercialise the use of Denvax, a dendritic cell based immunotherapy for treatment of solid cancers using the patient’s own mononuclear cells.